# Sibylle Loibl

Source: https://onco.cc/people/sibylle-loibl/  
OnCo record `sibylle-loibl` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Leads the German Breast Group, whose GeparX trials defined neoadjuvant chemotherapy and immunotherapy in breast cancer.

## Summary

Sibylle Loibl is Chief Executive Officer and Chair of the German Breast Group (GBG). Her specialisms are breast cancer, neoadjuvant trials and pathological complete response. She led GeparSixto, GeparNuevo and GeparDouze, trials of carboplatin and immunotherapy before surgery in triple-negative and HER2-positive breast cancer that shaped today's standards. Her Annals of Oncology paper on GeparNuevo reported a randomised phase II study of durvalumab added to anthracycline and taxane-based neoadjuvant therapy in early triple-negative breast cancer. Her German Breast Group profile and PubMed listing are linked.

## Fields

- Kind: Person
- Last checked: 2026-09-08
- Role: Chief Executive Officer and Chair, German Breast Group
- Specialisms: Breast cancer; Neoadjuvant trials; Pathologic complete response

## Sources

- German Breast Group: https://www.gbg.de/
- PubMed: https://pubmed.ncbi.nlm.nih.gov/?term=Loibl%20S%5BAuthor%5D%20neoadjuvant%20breast

## Connected records

- cancers: [HER2-positive breast cancer](https://onco.cc/cancers/breast-her2-positive/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- drugs: [Carboplatin](https://onco.cc/drugs/carboplatin/), [Durvalumab](https://onco.cc/drugs/durvalumab/)
- companies: [German Breast Group (GBG)](https://onco.cc/companies/gbg/)
- terms: [Pathologic complete response (pCR)](https://onco.cc/terms/pcr/)
- key papers: [ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer](https://onco.cc/key-papers/paper-ascent-nejm-2021/), [Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials](https://onco.cc/key-papers/paper-denkert-her2-low-pooled-neoadjuvant-lancet-oncol-2021/), [Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up](https://onco.cc/key-papers/paper-esmo-early-breast-cancer-guideline-ann-oncol-2024/), [Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto randomized clinical trial](https://onco.cc/key-papers/paper-hahnen-geparsixto-germline-brca-jama-oncol-2017/), [KATHERINE: switching to T-DM1 when HER2-positive breast cancer survives pre-surgery treatment](https://onco.cc/key-papers/paper-katherine-nejm-2019/), [OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer](https://onco.cc/key-papers/paper-olympia-nejm-2021/), [Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto](https://onco.cc/key-papers/paper-loibl-geparsixto-survival-hrd-ann-oncol-2018/), [Tailoring treatment to cancer risk and patient preference: the 2025 St Gallen International Breast Cancer Consensus Statement on individualizing therapy for patients with early breast cancer](https://onco.cc/key-papers/paper-st-gallen-2025-consensus-ann-oncol-2025/), [Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy](https://onco.cc/key-papers/paper-denkert-tils-neoadjuvant-pooled-lancet-oncol-2018/), [Understanding breast cancer complexity to improve patient outcomes: The St Gallen International Consensus Conference for the Primary Therapy of Individuals with Early Breast Cancer 2023](https://onco.cc/key-papers/paper-st-gallen-2023-consensus-ann-oncol-2023/)
- roadmaps: [Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease problem](https://onco.cc/roadmaps/tnbc-roadmap/)
- trials: [BrighTNess](https://onco.cc/trials/brightness/), [PENELOPE-B](https://onco.cc/trials/penelope-b/)

---
JSON: https://onco.cc/api/v1/entities/sibylle-loibl.json